A Phase 2 interventional study of Placebo and Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by PureTech. Active, not recruiting at 103 sites in 14 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by PureTech · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 9th largest by planned enrollment, is the only one that started in 2022, is one of 6 in phase 2, and was the 17th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:
PureTech · Sites in United States, Canada
Ages 40+
Assiut University · Sites in Egypt
Ages 18–80
By country, each count listing its studies:
pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 89 across the 21 interventional studies. Of the 17 that completed or were terminated, 9 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 21 have an industry lead sponsor. The 10 most frequent:
PureTech is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 4 (67%) have results posted.
PureTech has 3 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing pirfenidone in Idiopathic Pulmonary Fibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05842681Assiut UniversityAzithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis | 2027-01-01 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.
This study is a randomized, double-blind, being conducted at centers globally to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in 240 treatment naïve adult patients with IPF ≥ 40 years in age. Patients will be randomized in a ratio of 1:1:1:1 to receive treatment of LYT-100, pirfenidone, or placebo to be taken daily for up to 183 days (26 week treatment period) with the primary outcome of Rate of decline in Forced Vital Capacity (FVC; in mL) over 26 weeks. Secondary endpoints, including spirometry, inflammatory biomarkers, and patient-reported outcomes will also be evaluated.
After completion of the double-blind period of the study, patients may participate in a long-term extension to evaluate tolerability and long-term safety. Patients receiving LYT-100 in the double-blind period will continue the dose throughout the long-term extension. Patients receiving pirfenidone or placebo in the double-blind period will be re-randomized in a 1:1 ratio to receive LYT-100 550mg or 825mg TID dose throughout the long-term extension.
Key Inclusion Criteria:
Key Exclusion Criteria:
Cardiovascular diseases, any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo oral administration
Drug: Placebo
pirfenidone 801 mg TID oral administration
Drug: Pirfenidone
LYT-100 (Deupirfenidone) 550 mg TID oral administration
Drug: Deupirfenidone
LYT-100 (Deupirfenidone) 825 mg TID oral administration
Drug: Deupirfenidone
placebo
pirfenidone 801 mg TID
Deupirfenidone
Rate of decline in Forced Vital Capacity over 26 weeks (Part A)
Rate of decline in Forced Vital Capacity (FVC; in mL)
Time frame: 26 weeks
Forced Vital Capacity (FVC) percent predicted change (Part A)
FVC percent predicted (FVCpp) change from baseline to Week 26
Time frame: Baseline to Week 26
Time to hospitalization or mortality (Part A)
Time to hospitalization or mortality due to respiratory cause through 26 weeks
Time frame: 26 weeks
Time to Idiopathic Pulmonary Fibrosis (IPF) progression (Part A)
Time to IPF progression through 26 weeks, as defined by a decline in FVC% of 5% or greater or death
Time frame: 26 weeks
Forced Vital Capacity (FVC) percent predicted change (Part B)
FVC percent predicted (FVCpp) change from Week 26 to Week 52
Time frame: 26 Weeks
Rate of decline in Forced Vital Capacity over 26 weeks (Part B)
Rate of decline in Forced Vital Capacity (FVC; in mL) from Week 26 to Week 52
Time frame: 26 Weeks
Time to Idiopathic Pulmonary Fibrosis (IPF) progression (Part B)
Time to IPF progression from Week 26 to Week 52, as defined by a decline in FVC% of 5% or greater or death
Time frame: 26 Weeks
Showing the first 100 of 103 sites across 14 countries. Choose a country and city above to see the rest.
Plan to share: No
Ran from Jul 2022 to primary completion in Oct 2024, 26 months.
Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 26 months is close to that.
Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirfenidone
Idiopathic Pulmonary Fibrosis →
PureTech